Ankara University, School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey.
Medicana International Ankara Hospital, Ankara, Turkey.
Turk J Haematol. 2012 Sep;29(3):254-8. doi: 10.5152/tjh.2011.75. Epub 2012 Oct 5.
Patients with neutropenia due to cancer chemotherapy are prone to severe infections. Cancer patients canexperience >1 infectious episode during the same period of neutropenia. This study aimed to determine the etiologicaland clinical characteristics of secondary infectious episodes in cancer patients with febrile neutropenia and to identifythe factors associated with the risk of secondary infectious episodes.
All cancer patients that received antineoplastic chemotherapy at Ankara University, School ofMedicine, Department of Hematology between May 2004 and May 2005 and developed neutropenia were included in thestudy. Data were collected using survey forms that were completed during routine infectious diseases consultation visits.Categorical data were analyzed using the chi-square test, whereas Student's t-test was used for continuous variables.Multivariate logistic regression analysis was performed to identify independent predictors of secondary infections (SIs).
SIs were observed during 138 (53%) of 259 febrile neutropenic episodes. Of the 138 episodes, 89 (64.5%)occurred in male patients with a mean age of 40.9 years (range: 17-76 years). In total, 80% of the SIs were clinically ormicrobiologically documented. Factors on d 4 of the initial febrile episode were analyzed via a logistic regression model. The presence of a central intravenous catheter (OR: 3.01; P<0.001), acute myeloid leukemia (AML) as the underlyingdisease (OR: 2.12; P=0.008), diarrhea (OR: 4.59; P=0.005), and invasive aspergillosis (IA) during the initial febrileepisode (OR: 3.96; P=0.009) were statistically significant risk factors for SIs.
Among the cancer patients with neutropenia in the present study, AML as the underlying disease, thepresence of a central venous catheter, diarrhea, and IA during the initial febrile episode were risk factors for thedevelopment of SIs.
癌症化疗导致中性粒细胞减少的患者易发生严重感染。癌症患者在同一中性粒细胞减少期可经历>1 次感染发作。本研究旨在确定发热性中性粒细胞减少症癌症患者继发感染发作的病因和临床特征,并确定与继发感染发作风险相关的因素。
纳入 2004 年 5 月至 2005 年 5 月在安卡拉大学医学院血液科接受抗肿瘤化疗且发生中性粒细胞减少的所有癌症患者。使用在常规传染病会诊期间填写的调查问卷收集数据。使用卡方检验分析分类数据,使用学生 t 检验分析连续变量。采用多变量逻辑回归分析确定继发感染(SI)的独立预测因素。
在 259 例发热性中性粒细胞减少症中观察到 138 例(53%)继发感染。在 138 例感染中,89 例(64.5%)发生于男性患者,平均年龄为 40.9 岁(范围:17-76 岁)。总的来说,80%的 SI 有临床或微生物学依据。通过逻辑回归模型分析初始发热发作第 4 天的因素。存在中心静脉导管(OR:3.01;P<0.001)、基础疾病为急性髓系白血病(AML)(OR:2.12;P=0.008)、腹泻(OR:4.59;P=0.005)和初始发热发作期间侵袭性曲霉菌病(IA)(OR:3.96;P=0.009)是继发感染的统计学显著危险因素。
在本研究中性粒细胞减少症的癌症患者中,AML 作为基础疾病、中心静脉导管的存在、腹泻和初始发热发作期间的 IA 是继发感染发作的危险因素。